H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 14:51
Regulatory Filings
English 96.8 KB
2025-11-14 12:45
M&A Activity
English 25.3 KB
2025-11-14 12:45
Regulatory Filings
English 96.8 KB
2025-11-11 15:22
Regulatory Filings
English 116.4 KB
2025-11-11 15:22
Earnings Release
English 24.6 KB
2025-09-20 08:00
Regulatory Filings
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim / Quarterly Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for H. Lundbeck A

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea
009290
Kyivmedpreparat Logo
A leading pharmaceutical producer of antibacterial, generic, and original medicines in various forms.
Ukraine
KMED
KYONGBO PHARMACEUTICAL CO., LTD. Logo
Manufactures APIs and finished drugs, offering global CDMO services from development to production.
South Korea
214390
KYORIN Pharmaceutical Co., Ltd. Logo
Researches, develops, and sells a portfolio of ethical, generic, and OTC medicines.
Japan
4569
Kyowa Kirin Co.,Ltd. Logo
Develops antibody medicines for oncology, nephrology, immunology, and allergy.
Japan
4151
KyungdongPharm Logo
Develops and manufactures Rx/OTC drugs & APIs for cardiology and other chronic conditions.
South Korea
011040
KYUNG NAM PHARM.CO.,LTD. Logo
South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.
South Korea
053950
Kyverna Therapeutics, Inc. Logo
Developing CAR T-cell therapies for durable remission in autoimmune diseases.
United States of America
KYTX
Labiana S.A. Logo
Pharmaceutical CDMO for animal & human health with its own line of vaccines and generics.
Spain
LAB
Labocanna Spolka Akcyjna Logo
Cultivates and distributes medical marijuana and cannabinoid products for clinical and consumer use.
Poland
LCN

Talk to a Data Expert

Have a question? We'll get back to you promptly.